Skip to main content

Table 2 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in Norway.

From: Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

Week

44

45

46

47

48

49

50

51

52

53

Vaccinated population

 

No of cases

3

40

45

31

21

7

5

1

1

3

Population

32,766

266,276

501,087

697,952

873,561

1,105,676

1,397,413

1,675,256

1,891,882

1,891,654

Incidence(per 100,000)

9.16

15.02

8.98

4.44

2.40

0.63

0.36

0.06

0.05

0.16

Unvaccinated population

 

No of cases

2683

2540

1,581

854

449

182

80

33

16

12

Population

4,811,608

4,575,412

4,338,021

4,139,530

3,963,036

3,730,451

3,438,525

3,160,597

2,943,937

2,919,148

Incidence(per 100,000)

55.76

55.51

36.45

20.63

11.33

4.88

2.33

1.04

0.54

0.41

Vaccine effectiveness

 

Point estimate

84%

73%

75%

78%

79%

87%

85%

94%

90%

62%

95% confidence interval

50%-95%

63%-80%

67%-82%

69%-85%

68%-86%

72%-99%

62%-94%

58%-99%

27%-99%

-34%-90%

  1. Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 44-53, 2009) of the influenza pandemic in Norway. Vaccinees were considered immune eight days and later after vaccination.